



FAX RECEIVED

OCT 03 2000

GROUP 1600

## TELEFAX TRANSMITTAL COVER SHEET

OFFICIAL

Date: October 2, 2000Number of Pages: 3  
(Including Cover Sheet)

To:

Ex. Deborah Crouch

Company/Department:

GAU 1632

Fax Number:

703-308-4242

From:

William M. Blackstone

Company/Department:

Patent Department  
Rockville, Maryland

Fax Number:

(301) 948-9751  
(301) 948 - 7400

Subject/Reference:

KOK et al., USSN 09/390,846

Remarks:

**CONFIDENTIAL**

Please find attached:

Response to Restriction Requirement under 35 USC 121 (2 pages)

**Warning:**

The information contained in this facsimile message is attorney privileged and confidential information intended only for use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is wrongful and may subject you to civil liability. If you have received this communication in error, please immediately notify us by telephone, and return the original message to us at 1300 Piccard Drive #206, Rockville, MD 20850 via the U.S. Postal Service. Thank you.

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY:

**Date:**

~~10/2/15~~

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

KOK ET AL.

Serial Number: 09/390,846

Group Art Unit: 1632

Filed: September 14, 1999

Examiner: D. Crouch

For: COCCIDIOSIS POULTRY VACCINE

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 USC 121

Assistant Commissioner of Patents  
Washington, D.C. 20231

October 2, 2000


Sir:

In response to the Restriction Requirement issued September 5, 2000, Applicants elect, with traverse, Group I drawn to claims 1-3.

As the elected claims are directed to immunoreactive and/or antigenic determinants of Eimeria lactate dehydrogenase, and claims 11, 13 and 15 of Group II are directed to vaccines comprising such proteins and methods for their preparation and use, it is respectfully submitted that the examination of the protein claims and the vaccine claims would cover closely related

and overlapping art. Accordingly, it is respectfully requested that the vaccine claims be included in this application for review.

Respectfully submitted,

  
William M. Blackstone  
Attorney for Applicants  
Registration No. 29,772

Attorney Docket No. I/95150 US/D1  
AKZO NOBEL PATENT DEPARTMENT  
1300 Piccard Drive, Suite 206  
Rockville, Maryland 20850-4373  
Tel: (301) 948-7400  
Fax: (301) 948-9751

WMB:plb  
100kok.response